Cognition Therapeutics narrows Q2 net loss to $3.9 million from $6.7 million
Cognition Therapeutics reported a second-quarter 2026 net loss of $3.9 million, or $(0.04) per share, down from $6.7 million, or $(0.11) per share, a year earlier. Research and development expenses fell to $5.1 million from $11.5 million, while grant income also declined to $3.5 million from $7.1 million. The company said cash and restricted cash equivalents were $34.8 million at June 30, 2026, enough to fund operations into the fourth quarter of 2027.
Key points
- Net loss for the quarter ended June 30, 2026 was $3.9 million, versus $6.7 million in the same period of 2025
- Research and development expenses were $5.1 million, compared with $11.5 million a year earlier, driven by lower trial activity and compensation
- Cash, cash equivalents, and restricted cash equivalents were $34.8 million at June 30, 2026; the company expects cash to last into the fourth quarter of 2027
- The company plans to start a Phase 3 study in DLB psychosis in mid-2027 and received a Notice of Allowance for a zervimesine composition of matter patent
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.